all the latest information
, arranged by
therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Coupling germline genetics to interferon-alpha responses in polycythemia vera treatment
Pegylated interferon alfa-2 (PEG-IFN) induces high response rates in many patients with polycythemia vera (PV),...
What is the news about ropeginterferon?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR,...
Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms
The bone marrow niche is the local tissue microenvironment that maintains and regulates stem...
Phase II results from KRT-232, a first-in-class MDM2 inhibitor, for R/R MF failing JAK inhibitor therapy
Janus kinase (JAK) inhibitors (JAKi) are commonly used in patients with myelofibrosis (MF),...
The role of inflammation in MPN and its therapeutic management
Myeloproliferative neoplasms (MPN) are a group of hematological malignancies characterized by aberrant clonal expansion of hematopoietic...
Use of ruxolitinib in patients with severe COVID-19
Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor that has a good safety profile and is currently approved for the treatment of...
Molecular characterization of patients with polycythemia vera that develop resistance to hydroxyurea
Hydroxyurea is a cytoreductive agent offered to patients with polycythemia vera (PV) for treating...
How can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft-versus-host-disease?
During the American Association of Cancer Research (AACR) Virtual Annual...